الفهرس 
H EPATOCELLULAR C ARCINOMA (Only 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
Abstract
In our study we found there was no difference in tumor aggressiveness between patients with de novo HCC following DAA and patients with HCC that didn’t receive DAA regarding number of HFLs, total size of HFLs, malignant vascular invasion, suspicious malignant lymphadenopathy or extrahepatic metastasis HCC.
There were no differences regarding total size of tumor, or difference in vascular invasion, but there’s a difference in largest size of HFLs that was more significant in group (A)
Patients of group (A) with that received DAA showed lower child pugh score than those HCC of group (B) that didn’t treated with DAAs.
The Current study revealed 70 patients (87.5%) of group A achieved SVR with DAAs. there was no significant statistical value between both groups as regard type of intervention and type of DAAs that received as well as between type of DAAs and survival with(P =0.71).
There was no statistical significant difference between the 2 groups as regard type of of interventions that patients were eligible for.
There was no significant difference between 2 groups regarding survival of patients.